Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema

Simple item page
dc.contributor.authorGoel, Sen_US
dc.contributor.authorKumar, Aen_US
dc.contributor.authorRavani, RDen_US
dc.contributor.authorChandra, Pen_US
dc.contributor.authorChandra, Men_US
dc.contributor.authorKumar, Ven_US
dc.date.accessioned2020-04-10T02:03:51Z
dc.date.available2020-04-10T02:03:51Z
dc.date.issued2019-07
dc.description.abstractPurpose: To determine the effect of ultra-widefield fluorescein angiography (UWFFA)-guided targeted retinal photocoagulation (TRP) in branch retinal vein occlusion (BRVO) with macular edema after intravitreal Ranibizumab (RBZ). Methods: 33 eyes of 32 treatment naïve patients diagnosed as BRVO with macular edema were prospectively randomized to 0.5 mg Ranibizumab only (RBZ group) (n = 17) or Ranibizumab with UWFFA-guided laser (RBZ + TRP group) (n = 16). Both groups received three injections at monthly intervals and PRN henceforth. RBZ + TRP group additionally underwent UWFFA-guided TRP of peripheral capillary nonperfusion areas 1 week post injection. Outcome measures included improvement in visual acuity, central subfoveal thickness (CST), and the number of injections required with a minimum follow-up of 9 months. Results: Both groups showed significant improvement in mean BCVA (25.7 ± 8.19 letters, P < 0.001 vs. 23.38 ± 7.56 letters, P < 0.001; in RBZ and RBZ + TRP group, respectively) and reduction in mean central subfoveal thickness (379.12 ± 242.7 ?m, P < 0.001 vs. 253.75 ± 137.9 ?m, P < 0.001 in RBZ and RBZ + TRP group, respectively) at 9 months. The number of injections in the RBZ group (5.76 ± 1.3) was significantly greater than RBZ + TRP (4.06 ± 0.99) (P < 0.001). Both groups had significant improvement in contrast sensitivity and mean deviation on visual fields; however, the difference between the groups was not significant (P = 0.62 and P = 0.79, respectively). Conclusion: UWFFA-guided TRP reduced the number of injections of Ranibizumab in patients having BRVO with macular edema, while maintaining similar benefits in the improvement of BCVA, central subfoveal thickness without deleterious effect on the visual field, and contrast sensitivity.en_US
dc.identifier.affiliationsDr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS), New Delhi, Indiaen_US
dc.identifier.citationGoel S, Kumar A, Ravani RD, Chandra P, Chandra M, Kumar V. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema. Indian Journal of Ophthalmology. 2019 Jul; 67(7): 1105-1108en_US
dc.identifier.issn0301-4738
dc.identifier.issn1998-3689
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/197349
dc.languageenen_US
dc.publisherAll India Ophthalmological Societyen_US
dc.relation.issuenumber7en_US
dc.relation.volume67en_US
dc.source.urihttps://dx.doi.org/10.4103/ijo.IJO_1364_18en_US
dc.subjectAnti-vascular endothelial growth factor (anti-VEGF)en_US
dc.subjectbranch retinal vein occlusion (BRVO)en_US
dc.subjectmacular edemaen_US
dc.subjecttargeted retinal photocoagulation (TRP)en_US
dc.subjectultra-widefield fluorescein angiography (UWFFA)en_US
dc.titleComparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edemaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijo2019v67n7p1105.pdf
Size:
696.41 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Ophthalmology